Olmesartan medoxomil (BioDeep_00000279169)
代谢物信息卡片
Olmesartan medoxomil
化学式: C29H30N6O6 (558.2227)
中文名称: 奥美沙坦酯
谱图信息:
最多检出来源 Mentha canadensis(plant) 100%
分子结构信息
SMILES: CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O
InChI: InChI=1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34)
描述信息
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09C - Angiotensin ii receptor blockers (arbs), plain > C09CA - Angiotensin ii receptor blockers (arbs), plain
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist
D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor inhibitor with IC50 of 66.2 μM.
同义名列表
2 个代谢物同义名
数据库引用编号
9 个数据库交叉引用编号
- ChEBI: CHEBI:31932
- KEGGdrug: D01204
- PubChem: 130881
- Metlin: METLIN43884
- ChEMBL: CHEMBL1200692
- MeSH: Olmesartan Medoxomil
- CAS: 144689-63-4
- PMhub: MS000015871
- medchemexpress: HY-17005
分类词条
相关代谢途径
BioCyc(0)
PlantCyc(0)
代谢反应
36 个相关的代谢反应过程信息。
Reactome(36)
- Metabolism:
2MACA-CoA + CoA ⟶ Ac-CoA + PROP-CoA - Biological oxidations:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN - Phase I - Functionalization of compounds:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN - Metabolism:
3alpha,7alpha,12alpha-trihydroxy-5beta-cholest-24-one-CoA + CoA-SH ⟶ choloyl-CoA + propionyl CoA - Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Metabolism:
1-3-oxo-THA-CoA + CoA-SH ⟶ DHA-CoA + propionyl CoA - Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Metabolism:
1-3-oxo-THA-CoA + CoA-SH ⟶ DHA-CoA + propionyl CoA - Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Metabolism:
2MACA-CoA + CoA ⟶ Ac-CoA + PROP-CoA - Biological oxidations:
H+ + Oxygen + TPNH + progesterone ⟶ 11DCORST + H2O + TPN - Phase I - Functionalization of compounds:
H+ + Oxygen + TPNH + progesterone ⟶ 11DCORST + H2O + TPN - Metabolism:
3alpha,7alpha,12alpha-trihydroxy-5beta-cholest-24-one-CoA + CoA-SH ⟶ choloyl-CoA + propionyl CoA - Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Metabolism:
1-3-oxo-THA-CoA + CoA-SH ⟶ DHA-CoA + propionyl CoA - Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Metabolism:
2MACA-CoA + CoA ⟶ Ac-CoA + PROP-CoA - Biological oxidations:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN - Phase I - Functionalization of compounds:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN - Metabolism:
2MACA-CoA + CoA ⟶ Ac-CoA + PROP-CoA - Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Metabolism:
ATP + PROP-CoA + carbon dioxide ⟶ ADP + MEMA-CoA + Pi - Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Metabolism:
1-3-oxo-THA-CoA + CoA-SH ⟶ DHA-CoA + propionyl CoA - Biological oxidations:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN - Phase I - Functionalization of compounds:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN - Metabolism:
1-3-oxo-THA-CoA + CoA-SH ⟶ DHA-CoA + propionyl CoA - Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Hussam Murad, Osama Ahmed, Thamer Alqurashi, Mostafa Hussien. Olmesartan medoxomil self-microemulsifying drug delivery system reverses apoptosis and improves cell adhesion in trinitrobenzene sulfonic acid-induced colitis in rats.
Drug delivery.
2022 Dec; 29(1):2017-2028. doi:
10.1080/10717544.2022.2086939. [PMID: 35766160] - Yelda Komesli, Ercument Karasulu. Permeability of olmesartan medoxomil from lipid based and suspension formulations using an optimized HDM-PAMPA model.
Pharmaceutical development and technology.
2022 Jul; 27(6):749-757. doi:
10.1080/10837450.2022.2114495. [PMID: 35972198] - Xinjing Li, Enpan Mo, Lin Chen. Pharmacokinetics and Bioequivalence Evaluation of 2 Olmesartan Medoxomil and Amlodipine Besylate Fixed-Dose Combination Tablets in Healthy Chinese Volunteers Under Fasting and Fed Conditions.
Clinical pharmacology in drug development.
2022 06; 11(6):761-769. doi:
10.1002/cpdd.1086. [PMID: 35289500] - Shengfu Jiao, Yuxia Dong, Xiang Chang, Yanan Wu, Haifeng Li. Effects of α lipoic acid combined with olmesartan medoxomil on blood glucose and oxidation indicators in patients with diabetic nephropathy: A protocol for a parallel, randomized, double-blind, controlled clinical trial.
Medicine.
2022 Apr; 101(17):e29080. doi:
10.1097/md.0000000000029080. [PMID: 35512068] - Vivianne Presta, Ilaria Figliuzzi, Barbara Citoni, Giovanna Gallo, Allegra Battistoni, Giuliano Tocci, Massimo Volpe. ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients.
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension.
2021 May; 28(3):255-262. doi:
10.1007/s40292-021-00443-z. [PMID: 33710599] - Jia Yu, Wei Fang, Xing Guo, Haiyang Jiang, Peng Sun, Yufeng Liu, Xin Jin. The Clinical Efficacy of Clopidogrel Bisulfate Tablets Combined with Olmesartan Medoxomil for Ischemic Stroke with Hypertension and the Effect of Angiotensin II Type 1 Receptor Level on Prognosis.
Computational and mathematical methods in medicine.
2021; 2021(?):4487393. doi:
10.1155/2021/4487393. [PMID: 34745325] - Ye Zhu, Ze-Liang Li, Ao Ding, Hui Yang, Wei-Ping Zhu, Tong-Xia Cui, Hui-Tao Zhang, Hua Zhang. Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice.
Drug design, development and therapy.
2019; 13(?):3657-3667. doi:
10.2147/dddt.s217826. [PMID: 31695333] - A E Pulles, S C Mastbergen, W Foppen, R E G Schutgens, F P J G Lafeber, L F D van Vulpen. The combination of urinary CTX-II and serum CS-846: Promising biochemical markers to predict radiographic progression of haemophilic arthropathy-An exploratory study.
Haemophilia : the official journal of the World Federation of Hemophilia.
2018 07; 24(4):e278-e280. doi:
10.1111/hae.13554. [PMID: 30044054] - Nilima T Pandya, Parva Jani, Jigar Vanza, Hemal Tandel. Solid lipid nanoparticles as an efficient drug delivery system of olmesartan medoxomil for the treatment of hypertension.
Colloids and surfaces. B, Biointerfaces.
2018 May; 165(?):37-44. doi:
10.1016/j.colsurfb.2018.02.011. [PMID: 29453084] - George L Bakris, Lin Zhao, Stuart Kupfer, Attila Juhasz, Michie Hisada, Eric Lloyd, Suzanne Oparil. Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease.
Journal of clinical hypertension (Greenwich, Conn.).
2018 04; 20(4):694-702. doi:
10.1111/jch.13230. [PMID: 29504252] - Sarwar Beg, Sumant Saini, Shantanu Bandopadhyay, O P Katare, Bhupinder Singh. QbD-driven development and evaluation of nanostructured lipid carriers (NLCs) of Olmesartan medoxomil employing multivariate statistical techniques.
Drug development and industrial pharmacy.
2018 Mar; 44(3):407-420. doi:
10.1080/03639045.2017.1395459. [PMID: 29048242] - Arun B, Narendar D, Kishan Veerabrahma. Development of olmesartan medoxomil lipid-based nanoparticles and nanosuspension: preparation, characterization and comparative pharmacokinetic evaluation.
Artificial cells, nanomedicine, and biotechnology.
2018 Feb; 46(1):126-137. doi:
10.1080/21691401.2017.1299160. [PMID: 28290712] - Akitoshi Tatsumi, Sachiyo Inoue, Tsuneo Hamaguchi, Seigo Iwakawa. The Effect of Ethanol on the Hydrolysis of Ester-Type Drugs by Human Serum Albumin.
Biological & pharmaceutical bulletin.
2018 Feb; 41(2):277-280. doi:
10.1248/bpb.b17-00680. [PMID: 29176265] - Mi-Yeon Yu, Dong Ki Kim, Jung Hwan Park, Sung Joon Shin, Sang Ho Lee, Bum Soon Choi, Chun Soo Lim, Ho Jun Chin. Albuminuria during treatment with angiotensin type II receptor blocker is a predictor for GFR decline among non-diabetic hypertensive CKD patients.
PloS one.
2018; 13(8):e0202676. doi:
10.1371/journal.pone.0202676. [PMID: 30148871] - Devender Kodati, Harish Kaushik Kotakonda, Narsimhareddy Yellu. Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension.
European journal of drug metabolism and pharmacokinetics.
2017 Aug; 42(4):573-581. doi:
10.1007/s13318-016-0371-0. [PMID: 27535556] - Mi Jin Oh, Hyun Hwan Hwang, Hyun Gyu Kim, Geun Hyeog Lee, Yun-Seok Cho, Sun Young Lee, Soo Yeon Kang, Kyung Hee Cho, Yun Young Lee, Yun Jeong Lee, Choon-Gon Jang, Seok-Yong Lee. Bioequivalence Study of a New Fixed-dose Combination Tablet Containing S-Amlodipine Nicotinate and Olmesartan Medoxomil in Healthy Korean Male Subjects.
Clinical therapeutics.
2017 Jul; 39(7):1371-1379. doi:
10.1016/j.clinthera.2017.05.355. [PMID: 28625505] - Vikram Kaithwas, Chander Parkash Dora, Varun Kushwah, Sanyog Jain. Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability.
Colloids and surfaces. B, Biointerfaces.
2017 Jun; 154(?):10-20. doi:
10.1016/j.colsurfb.2017.03.006. [PMID: 28284054] - Mounika Nooli, Naveen Chella, Hitesh Kulhari, Nalini R Shastri, Ramakrishna Sistla. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation.
Drug development and industrial pharmacy.
2017 Apr; 43(4):611-617. doi:
10.1080/03639045.2016.1275666. [PMID: 28005442] - H Li, L Y Shi, L Chen, Y Z Lu, B Yu, G X Qi. [Impact of olmesartan medoxomil on atherosclerosis lesions in apolipoprotein E knockout mice].
Zhonghua yi xue za zhi.
2016 Aug; 96(31):2502-6. doi:
10.3760/cma.j.issn.0376-2491.2016.31.013. [PMID: 27562051] - Shinsuke Isobe, Naro Ohashi, Sayaka Ishigaki, Takayuki Tsuji, Yukitoshi Sakao, Akihiko Kato, Hiroaki Miyajima, Yoshihide Fujigaki, Akira Nishiyama, Hideo Yasuda. Augmented circadian rhythm of the intrarenal renin-angiotensin systems in anti-thymocyte serum nephritis rats.
Hypertension research : official journal of the Japanese Society of Hypertension.
2016 May; 39(5):312-20. doi:
10.1038/hr.2015.151. [PMID: 26739872] - Il Suk Sohn, Chong-Jin Kim, Byung-Hee Oh, Taek-Jong Hong, Chang-Gyu Park, Byung-Soo Kim, Woo-Baek Chung. Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
2016 Apr; 16(2):129-38. doi:
10.1007/s40256-015-0156-x. [PMID: 26691333] - Norio Susa, Yayoi Nishida, Yoichi Yada, Tomohiro Nakayama, Satoshi Asai, Yasuo Takahashi. Comparative effect of fixed-dose combination tablets of candesartan cilexetil/amlodipine versus olmesartan medoxomil/azelnidipine on laboratory parameters in patients with hypertension: a retrospective cohort study.
Clinical and experimental hypertension (New York, N.Y. : 1993).
2016; 38(2):173-9. doi:
10.3109/10641963.2015.1081214. [PMID: 26453437] - Verdiana Ravarotto, Elisa Pagnin, Giuseppe Maiolino, Antonio Fragasso, Gianni Carraro, Barbara Rossi, Lorenzo A Calò. The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling.
Journal of the renin-angiotensin-aldosterone system : JRAAS.
2015 Dec; 16(4):1245-50. doi:
10.1177/1470320315594324. [PMID: 26240115] - Jose Luis Ulla-Rocha, Susana Lopez-Piñeiro, Manuel Puga-Gimenez. [Acute renal failure secondary to diarrhea due to sprue like-enteropathy associated with olmesartan].
Gastroenterologia y hepatologia.
2015 Oct; 38(8):514-5. doi:
10.1016/j.gastrohep.2014.11.007. [PMID: 25534549] - Yoshiteru Tada, Kenji Yagi, Masaaki Uno, Nobuhisa Matsushita, Yasuhisa Kanematsu, Kazuyuki Kuwayama, Kenji Shimada, Kyoko Nishi, Motohiro Hirasawa, Junichiro Satomi, Keiko T Kitazato, Teruyoshi Kageji, Eiji Matsuura, Shinji Nagahiro. Improvement of Plasma Biomarkers after Switching Stroke Patients from Other Angiotensin II Type I Receptor Blockers to Olmesartan.
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
2015 Jul; 24(7):1487-92. doi:
10.1016/j.jstrokecerebrovasdis.2015.03.015. [PMID: 25891757] - Aurigena Antunes de Araújo, Pedro Brito Borba, Fernando Henrique Destefani de Souza, Anália Cristina Nogueira, Taís Suassuna Saldanha, Thayse Emanuele Franklin Araújo, Aldemara Ingrid da Silva, Raimundo Fernandes de Araújo Júnior. In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity.
Biological & pharmaceutical bulletin.
2015; 38(5):746-52. doi:
10.1248/bpb.b14-00847. [PMID: 25947920] - Jung Nam An, Jin Ho Hwang, Jung Pyo Lee, Ho Jun Chin, Sejoong Kim, Dong Ki Kim, Suhnggwon Kim, Jung Hwan Park, Sung Joon Shin, Sang Ho Lee, Bum Soon Choi, Chun Soo Lim. The Decrement of Hemoglobin Concentration with Angiotensin II Receptor Blocker Treatment Is Correlated with the Reduction of Albuminuria in Non-Diabetic Hypertensive Patients: Post-Hoc Analysis of ESPECIAL Trial.
PloS one.
2015; 10(6):e0128632. doi:
10.1371/journal.pone.0128632. [PMID: 26098847] - En Shu, Hiroyuki Kanoh, Mariko Seishima. Scleroderma renal crisis following pericardial effusion in a Japanese female.
The Journal of dermatology.
2014 Sep; 41(9):824-6. doi:
10.1111/1346-8138.12574. [PMID: 25039404] - Jung-Woo Chae, In-Hwan Baek, Jeong-Won Seo, Sang-Hoon Jung, Hyun-Moon Back, Byung-Jeong Song, Byung-Yo Lee, Hwi-Yeol Yun, Wonku Kang, Kwang-Il Kwon. Development of a population pharmacokinetic model to describe olmesartan medoxomil/ hydrochlorothiazide (20/12.5 mg) FDC tablet in male healthy South Korean subjects.
International journal of clinical pharmacology and therapeutics.
2014 Aug; 52(8):676-83. doi:
10.5414/cp202046. [PMID: 24849193] - Dong-yang Liu, Ji Jiang, Chen-guang Wang, Jian-yan Zhang, Pei Hu. Pharmacokinetics and tolerability of olmesartan medoxomil plus hydrochlorothiazide combination in healthy Chinese subjects: drug-drug interaction, bioequivalence, and accumulation.
International journal of clinical pharmacology and therapeutics.
2014 Apr; 52(4):321-7. doi:
10.5414/cp202007. [PMID: 24472401] - Bapi Gorain, Hira Choudhury, Amit Kundu, Lipi Sarkar, Sanmoy Karmakar, P Jaisankar, Tapan Kumar Pal. Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats.
Colloids and surfaces. B, Biointerfaces.
2014 Mar; 115(?):286-94. doi:
10.1016/j.colsurfb.2013.12.016. [PMID: 24388859] - Lorenzo A Calò, Lucia Dal Maso, Elisa Pagnin, Verdiana Ravarotto, Monica Facco, Elisa Boscaro, Giuseppe Maiolino, Achille C Pessina, Gian Paolo Rossi. Effect of olmesartan medoxomil on number and survival of circulating endothelial progenitor cells and calcitonin gene related peptide in hypertensive patients.
Journal of hypertension.
2014 Jan; 32(1):193-9. doi:
10.1097/hjh.0b013e32836522c3. [PMID: 24309489] - Ling He, Prachi Wickremasingha, James Lee, Ben Tao, Jeanne Mendell-Harary, Joseph Walker, Douglas Wight. The effects of colesevelam HCl on the single-dose pharmacokinetics of glimepiride, extended-release glipizide, and olmesartan medoxomil.
Journal of clinical pharmacology.
2014 Jan; 54(1):61-9. doi:
10.1002/jcph.180. [PMID: 24019110] - Changyun Jin, Ji-Young Jeon, Yong-Jin Im, Jin-A Jung, Yunjeong Kim, Kwangkyu Park, Yoonho Choi, Soo-Wan Chae, Min-Gul Kim. Pharmacokinetic properties and bioequivalence of olmesartan medoxomil/hydrochlorothiazide in healthy Korean male subjects.
International journal of clinical pharmacology and therapeutics.
2014 Jan; 52(1):64-72. doi:
10.5414/cp201991. [PMID: 24290413] - Jan Menne, Eberhard Ritz, Luis M Ruilope, Christos Chatzikyrkou, Giancarlo Viberti, Hermann Haller. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.
Journal of the American Heart Association.
2014; 3(2):e000810. doi:
10.1161/jaha.114.000810. [PMID: 24772521] - Z-C Li, H-Y Yu, X-X Wang, M Zhang, J-P Wang. Olmesartan medoxomil reverses left ventricle hypertrophy and reduces inflammatory cytokine IL-6 in the renovascular hypertensive rats.
European review for medical and pharmacological sciences.
2013 Dec; 17(24):3318-22. doi:
. [PMID: 24379062] - Yayoi Nishida, Yasuo Takahashi, Norio Susa, Nobukazu Kanou, Tomohiro Nakayama, Satoshi Asai. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Cardiovascular diabetology.
2013 Nov; 12(?):159. doi:
10.1186/1475-2840-12-159. [PMID: 24180232] - Tomoko Ishizuka, Yasushi Yoshigae, Nobuyuki Murayama, Takashi Izumi. Different hydrolases involved in bioactivation of prodrug-type angiotensin receptor blockers: carboxymethylenebutenolidase and carboxylesterase 1.
Drug metabolism and disposition: the biological fate of chemicals.
2013 Nov; 41(11):1888-95. doi:
10.1124/dmd.113.053595. [PMID: 23946449] - Andrew J Lewin, Joseph L Izzo, Michael Melino, James Lee, Victor Fernandez, Reinilde Heyrman. Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age.
Drugs & aging.
2013 Jul; 30(7):549-60. doi:
10.1007/s40266-013-0072-1. [PMID: 23549909] - Jasmina Varagic, Sarfaraz Ahmad, Jessica L VonCannon, Norihito Moniwa, K Bridget Brosnihan, Jan Wysocki, Daniel Batlle, Carlos M Ferrario. Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats.
American journal of hypertension.
2013 May; 26(5):583-90. doi:
10.1093/ajh/hps090. [PMID: 23459599] - Mohammed I El-Gamal, Hanan S Anbar, Hye Jin Chung, Hyun-Il Kim, Young-Jin Cho, Bong Sang Lee, Sun Ahe Lee, Ji Yun Moon, Dong Jin Lee, Dow Kwon, Won-Jai Choi, Hong-Ryeol Jeon, Chang-Hyun Oh. Discovery of olmesartan hexetil: a new potential prodrug of olmesartan.
Bioorganic & medicinal chemistry letters.
2013 Mar; 23(5):1347-50. doi:
10.1016/j.bmcl.2012.12.090. [PMID: 23347686] - Tadashi Uramatsu, Tomoya Nishino, Yoko Obata, Yohei Sato, Akira Furusu, Takehiko Koji, Toru Miyazaki, Shigeru Kohno. Involvement of apoptosis inhibitor of macrophages in a rat hypertension model with nephrosclerosis: possible mechanisms of action of olmesartan and azelnidipine.
Biological & pharmaceutical bulletin.
2013; 36(8):1271-7. doi:
10.1248/bpb.b12-00965. [PMID: 23902971] - Shinji Kosaka, Nicolas Pelisch, Matlubur Rahman, Daisuke Nakano, Hirofumi Hitomi, Hiroyuki Kobori, Noriyasu Fukuoka, Hideki Kobara, Hirohito Mori, Tsutomu Masaki, Ludek Cervenka, Yasuo Matsumura, Hitoshi Houchi, Akira Nishiyama. Effects of angiotensin II AT₁-receptor blockade on high fat diet-induced vascular oxidative stress and endothelial dysfunction in Dahl salt-sensitive rats.
Journal of pharmacological sciences.
2013; 121(2):95-102. doi:
10.1254/jphs.12169fp. [PMID: 23337436] - Kazuki Noda, Maki Hosoya, Sota Nakajima, Junko Ohashi, Yoshihiro Fukumoto, Hiroaki Shimokawa. Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.
The Tohoku journal of experimental medicine.
2012 12; 228(4):305-15. doi:
10.1620/tjem.228.305. [PMID: 23124103] - Claudio Ferri, Livia Ferri. Renin-angiotensin-aldosterone system blockade is safe and effective in elderly hypertensive patients with and without impaired renal function.
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension.
2012 Dec; 19(4):197-8. doi:
10.1007/bf03297629. [PMID: 23430662] - Thomas G Wells, Douglas L Blowey, Janice E Sullivan, Jeffrey Blumer, Joseph R Sherbotie, Saeheum Song, Shashank Rohatagi, Reinilde Heyrman, Daniel E Salazar. Pharmacokinetics of olmesartan medoxomil in pediatric patients with hypertension.
Paediatric drugs.
2012 Dec; 14(6):401-9. doi:
10.2165/11631450-000000000-00000. [PMID: 22880942] - Xia Chen, Pei Hu, Ji Jiang, Tao Liu, Wen Zhong, Hongzhong Liu, Qian Zhao. Pharmacokinetic and pharmacodynamic profiles of a fixed-dose combination of olmesartan medoxomil and amlodipine in healthy Chinese males and females.
Clinical drug investigation.
2012 Dec; 32(12):783-90. doi:
10.1007/s40261-012-0026-0. [PMID: 23160920] - Ettore Malacco, Stefano Omboni, Jean-Michel Mallion, Massimo Volpe. Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis.
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension.
2012 Dec; 19(4):213-22. doi:
10.1007/bf03297633. [PMID: 23430666] - Dean J Kereiakes, Steven G Chrysant, Joseph L Izzo, Thomas Littlejohn, Michael Melino, James Lee, Victor Fernandez, Reinilde Heyrman. Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.
Cardiovascular diabetology.
2012 Oct; 11(?):134. doi:
10.1186/1475-2840-11-134. [PMID: 23110471] - C Enzensberger, K Eskef, A Schwarze, D Faas, R Axt-Fliedner. Course and outcome of pregnancy after maternal exposure to angiotensin-II-receptor blockers--case report and review of the literature.
Ultraschall in der Medizin (Stuttgart, Germany : 1980).
2012 Oct; 33(5):493-6. doi:
10.1055/s-0029-1245942. [PMID: 21630188] - Christos Chatzikyrkou, Jan Menne. Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.
Expert review of cardiovascular therapy.
2012 Sep; 10(9):1087-92. doi:
10.1586/erc.12.100. [PMID: 23098143] - Ikuo Saito, Toshio Kushiro, Natsuko Zenimura, Yasuyuki Matsushita, Kei Sagawa, Katsutoshi Hiramatsu, Fumie Yamaguchi. Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan.
Journal of nephrology.
2012 Sep; 25(5):699-708. doi:
10.5301/jn.5000043. [PMID: 22020401] - Kazuki Noda, Miyuki Kobara, Junichi Hamada, Yusuke Yoshifuji, Tatsuya Shiraishi, Takuya Tanaka, Jiahong Wang, Hiroe Toba, Tetsuo Nakata. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
Journal of cardiovascular pharmacology.
2012 Aug; 60(2):140-9. doi:
10.1097/fjc.0b013e318258f8ce. [PMID: 22549451] - Jennifer M Sasser, Natasha C Moningka, Tatsiana Tsarova, Chris Baylis. Nebivolol does not protect against 5/6 ablation/infarction induced chronic kidney disease in rats - comparison with angiotensin II receptor blockade.
Life sciences.
2012 Jul; 91(1-2):54-63. doi:
10.1016/j.lfs.2012.06.005. [PMID: 22727796] - Tomohiro Ishimaru, Junji Ishida, Shoko Nakamura, Misuzu Hashimoto, Tanomu Matsukura, Ayumi Nakamura, Satoshi Kunita, Fumihiro Sugiyama, Ken-Ichi Yagami, Akiyoshi Fukamizu. Short-term suppression of the renin-angiotensin system in mice associated with hypertension during pregnancy.
Molecular medicine reports.
2012 07; 6(1):28-32. doi:
10.3892/mmr.2012.886. [PMID: 22552605] - Yanjie Huang, Tatsuo Yamamoto, Taro Misaki, Hiroyuki Suzuki, Akashi Togawa, Naro Ohashi, Hirotaka Fukasawa, Yoshihide Fujigaki, Atsuhiro Ichihara, Akira Nishiyama, Takaaki Senbonmatsu, Naoki Ikegaya, Akira Hishida. Enhanced intrarenal receptor-mediated prorenin activation in chronic progressive anti-thymocyte serum nephritis rats on high salt intake.
American journal of physiology. Renal physiology.
2012 Jul; 303(1):F130-8. doi:
10.1152/ajprenal.00275.2011. [PMID: 22496409] - Choon O Kim, Sung K Cho, Eun S Oh, Min S Park, Jae-Yong Chung. Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan.
Journal of cardiovascular pharmacology.
2012 Jul; 60(1):49-54. doi:
10.1097/fjc.0b013e3182576098. [PMID: 22494992] - Yao-Chen Chuang, Ming-Shiou Wu, Yi-Kai Su, Kwang-Ming Fang. Effects of olmesartan on arterial stiffness in rats with chronic renal failure.
Cardiovascular diabetology.
2012 Jun; 11(?):66. doi:
10.1186/1475-2840-11-66. [PMID: 22694778] - Minamo Ono, Michio Fukuda, Toshiyuki Miura, Masashi Mizuno, Yoko Kato, Ryo Sato, Takehiro Naito, Hiroyuki Togawa, Yuji Sasakawa, Tatsuya Tomonari, Tadashi Ichikawa, Yuichi Shirasawa, Akinori Ito, Atsuhiro Yoshida, Genjiro Kimura. Predictors of proteinuria reduction by monotherapy with an angiotensin receptor blocker, olmesartan.
Journal of the renin-angiotensin-aldosterone system : JRAAS.
2012 Jun; 13(2):239-43. doi:
10.1177/1470320311434817. [PMID: 22333486] - Takahito Moriyama, Yuki Tsuruta, Chiari Kojima, Mitsuyo Itabashi, Hidekazu Sugiura, Takashi Takei, Tetsuya Ogawa, Keiko Uchida, Ken Tsuchiya, Kosaku Nitta. Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease.
International urology and nephrology.
2012 Jun; 44(3):841-5. doi:
10.1007/s11255-011-9991-0. [PMID: 21626132] - Sonia Gandhi, B P Srinivasan, Atul Sureshrao Akarte. Effective blockade of RAAS by combination of aliskiren and olmesartan improves glucose homeostasis, glomerular filtration rate along with renal variables in streptozotocin induced diabetic rats.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2012 May; 46(1-2):32-42. doi:
10.1016/j.ejps.2012.02.002. [PMID: 22349361] - Duo Wei, Wan-Yuan He, Qian-Zhou Lv. Effect of nisoldipine and olmesartan on endothelium-dependent vasodilation in essential hypertensive patients.
CNS neuroscience & therapeutics.
2012 May; 18(5):400-5. doi:
10.1111/j.1755-5949.2012.00304.x. [PMID: 22533725] - Myung J Kang, Hyung S Kim, Ho S Jeon, Jong H Park, Bong S Lee, Byeong K Ahn, Ki Y Moon, Young W Choi. In situ intestinal permeability and in vivo absorption characteristics of olmesartan medoxomil in self-microemulsifying drug delivery system.
Drug development and industrial pharmacy.
2012 May; 38(5):587-96. doi:
10.3109/03639045.2011.619194. [PMID: 21988221] - Tadashi Sofue, Hideyasu Kiyomoto, Hiroyuki Kobori, Maki Urushihara, Yoko Nishijima, Kumiko Kaifu, Taiga Hara, Sachiko Matsumoto, Atsuhiko Ichimura, Hiroyuki Ohsaki, Hirofumi Hitomi, Hiroshi Kawachi, Melvin R Hayden, Adam Whaley-Connell, James R Sowers, Sadayoshi Ito, Masakazu Kohno, Akira Nishiyama. Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.
American journal of hypertension.
2012 May; 25(5):604-11. doi:
10.1038/ajh.2012.1. [PMID: 22318512] - Areeba Ahmad, Riaz Ahmad. Understanding the mechanism of hepatic fibrosis and potential therapeutic approaches.
Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.
2012 May; 18(3):155-67. doi:
10.4103/1319-3767.96445. [PMID: 22626794] - K Manotham, B Ongvilawan, P Urusopone, S Chetsurakarn, J Tanamai, P Limkuansuwan, K Tungsanga, S Eiam-Ong. Angiotensin II receptor blocker partially ameliorated intrarenal hypoxia in chronic kidney disease patients: a pre-/post-study.
Internal medicine journal.
2012 Apr; 42(4):e33-7. doi:
10.1111/j.1445-5994.2011.02610.x. [PMID: 22611567] - Jan Menne, Joseph L Izzo, Sadayoshi Ito, Andrzej Januszewicz, Shigehiro Katayama, Christos Chatzykirkou, Albert Mimran, Ton J Rabelink, Eberhard Ritz, Luis M Ruilope, Lars C Rump, Giancarlo Viberti, Hermann Haller. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension.
Journal of hypertension.
2012 Apr; 30(4):811-8; discussion 818. doi:
10.1097/hjh.0b013e328351856d. [PMID: 22418908] - Kazi Rafiq, Takahisa Noma, Yoshihide Fujisawa, Yasuhiro Ishihara, Yoshie Arai, A H M Nurun Nabi, Fumiaki Suzuki, Yukiko Nagai, Daisuke Nakano, Hirofumi Hitomi, Kento Kitada, Maki Urushihara, Hiroyuki Kobori, Masakazu Kohno, Akira Nishiyama. Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation.
Circulation.
2012 Mar; 125(11):1402-13. doi:
10.1161/circulationaha.111.064097. [PMID: 22328542] - Tsuyoshi Homma, Hiroko Sonoda, Kenichi Manabe, Kiyoshi Arai, Makoto Mizuno, Toshio Sada, Masahiro Ikeda. Activation of renal angiotensin type 1 receptor contributes to the pathogenesis of progressive renal injury in a rat model of chronic cardiorenal syndrome.
American journal of physiology. Renal physiology.
2012 Mar; 302(6):F750-61. doi:
10.1152/ajprenal.00494.2011. [PMID: 22160776] - Daisuke Nakano, Bai Lei, Kento Kitada, Hirofumi Hitomi, Hiroyuki Kobori, Hirohito Mori, Kazushi Deguchi, Tsutomu Masaki, Tohru Minamino, Akira Nishiyama. Aldosterone does not contribute to renal p21 expression during the development of angiotensin II-induced hypertension in mice.
American journal of hypertension.
2012 Mar; 25(3):354-8. doi:
10.1038/ajh.2011.224. [PMID: 22113172] - Tsukasa Nakamura, Eiichi Sato, Mayuko Amaha, Yasuhiro Kawagoe, Sayaka Maeda, Sho-ichi Yamagishi. Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria.
Journal of the renin-angiotensin-aldosterone system : JRAAS.
2012 Mar; 13(1):122-7. doi:
10.1177/1470320311422580. [PMID: 21946392] - Natasha C Moningka, Tatsiana Tsarova, Jennifer M Sasser, Chris Baylis. Protective actions of nebivolol on chronic nitric oxide synthase inhibition-induced hypertension and chronic kidney disease in the rat: a comparison with angiotensin II receptor blockade.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2012 Mar; 27(3):913-20. doi:
10.1093/ndt/gfr449. [PMID: 21856762] - Tomoko Ishizuka, Izumi Fujimori, Atsuko Nishida, Hidetaka Sakurai, Yasushi Yoshigae, Kaori Nakahara, Atsushi Kurihara, Toshihiko Ikeda, Takashi Izumi. Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
Drug metabolism and disposition: the biological fate of chemicals.
2012 Feb; 40(2):374-80. doi:
10.1124/dmd.111.041475. [PMID: 22086979] - Hiroki Fujita, Hiromi Fujishima, Tsukasa Morii, Takuya Sakamoto, Koga Komatsu, Mihoko Hosoba, Takuma Narita, Keiko Takahashi, Takamune Takahashi, Yuichiro Yamada. Modulation of renal superoxide dismutase by telmisartan therapy in C57BL/6-Ins2(Akita) diabetic mice.
Hypertension research : official journal of the Japanese Society of Hypertension.
2012 Feb; 35(2):213-20. doi:
10.1038/hr.2011.176. [PMID: 22072110] - Pinaki Sengupta, Utpal Nandi, Tapan Kumar Pal. Development of safety profile evaluating pharmacokinetics, pharmacodynamics and toxicity of a combination of pioglitazone and olmesartan medoxomil in Wistar albino rats.
Regulatory toxicology and pharmacology : RTP.
2012 Feb; 62(1):7-15. doi:
10.1016/j.yrtph.2011.12.008. [PMID: 22203042] - Kouichi Utsumi, Fumihiko Yasuda, Yoko Watanabe, Seiichiro Higo, Akio Hirama, Emiko Fujita, Kae Ueda, Akiko Mii, Tomohiro Kaneko, Masahiro Mishina, Yasuhiko Iino, Yasuo Katayama. Effects of olmesartan and imidapril on the plasma adiponectin, P-selectin, and MDA-LDL levels of diabetic nephropathy patients.
Clinica chimica acta; international journal of clinical chemistry.
2012 Jan; 413(1-2):348-9. doi:
10.1016/j.cca.2011.09.024. [PMID: 21983097] - Arun Prasath Lakshmanan, Rajarajan A Thandavarayan, Kenichi Watanabe, Flori R Sari, Harima Meilei, Vijayasree V Giridharan, Vijayakumar Sukumaran, Vivian Soetikno, Somasundaram Arumugam, Kenji Suzuki, Makoto Kodama. Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice.
Molecular and cellular endocrinology.
2012 Jan; 348(1):104-11. doi:
10.1016/j.mce.2011.07.041. [PMID: 21827824] - Hirokazu Honda, Nozomu Hosaka, Yumie Aoshima, Yuki Hirai, Tetsuo Michihata, Tadao Akizawa. Olmesartan medoxomil is associated with decreased plasma AGEs, pentosidine, and N-(epsilon)-carboxymethyl-lysine levels in hemodialysis patients.
Clinical and experimental hypertension (New York, N.Y. : 1993).
2012; 34(1):17-23. doi:
10.3109/10641963.2011.628726. [PMID: 22149003] - Seiya Shimoda, Rieko Goto, Noboru Furukawa, Kaku Tsuruzoe, Junji Kawashima, Shinsuke Iwashita, Takako Maeda, Shinji Ichimori, Kenshi Ichinose, Kenro Nishida, Eiichi Araki. Effects of olmesartan, an angiotensin II receptor blocker, on peripheral insulin sensitivity in Japanese subjects with type 2 diabetes and hypertension.
Internal medicine (Tokyo, Japan).
2012; 51(16):2091-6. doi:
10.2169/internalmedicine.51.7408. [PMID: 22892484] - Masashi Nishida, Yasuko Okumura, Tatsujiro Oka, Kentaro Toiyama, Seiichiro Ozawa, Toshiyuki Itoi, Kenji Hamaoka. The role of apelin on the alleviative effect of Angiotensin receptor blocker in unilateral ureteral obstruction-induced renal fibrosis.
Nephron extra.
2012 Jan; 2(1):39-47. doi:
10.1159/000337091. [PMID: 22619666] - Hiroo Kumagai, Takashi Oda, Naoki Ohshima, Hanako Takechi, Kojiro Yamamoto, Takahiro Uchida, Atsushi Watanabe, Hiroki Tadano, Hidehito Matsubara, Masamitsu Senda. [Recent advance in kidney and hypertension research].
Nihon Jinzo Gakkai shi.
2012; 54(1):1-10. doi:
NULL. [PMID: 22413572] - Jiancheng Xu, Qi Zhou, Wei Xu, Lu Cai. Endoplasmic reticulum stress and diabetic cardiomyopathy.
Experimental diabetes research.
2012; 2012(?):827971. doi:
10.1155/2012/827971. [PMID: 22144992] - Ryuji Suzuki, Hirokazu Honda, Kazuhiko Niikura, Tadao Akizawa. Olmesartan medoxomil treatment is associated with decreased plasma B-type natriuretic peptide levels in patients on hemodialysis.
Clinical and experimental hypertension (New York, N.Y. : 1993).
2012; 34(2):125-31. doi:
10.3109/10641963.2011.601379. [PMID: 21967019] - Massimo Volpe, Carmine Savoia. New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil.
Integrated blood pressure control.
2012; 5(?):19-25. doi:
10.2147/ibpc.s13784. [PMID: 22457601] - Takeshi Takami, Shigeru Yamano, Sadanori Okada, Mio Sakuma, Takeshi Morimoto, Hiroshi Hashimoto, Satoshi Somekawa, Yoshihiko Saito. Major risk factors for the appearance of white-matter lesions on MRI in hypertensive patients with controlled blood pressure.
Vascular health and risk management.
2012; 8(?):169-76. doi:
10.2147/vhrm.s30507. [PMID: 22454561] - Qi Guo, Takefumi Mori, Yue Jiang, Chunyan Hu, Yusuke Ohsaki, Yoshimi Yoneki, Takashi Nakamichi, Susumu Ogawa, Hiroshi Sato, Sadayoshi Ito. Losartan modulates muscular capillary density and reverses thiazide diuretic-exacerbated insulin resistance in fructose-fed rats.
Hypertension research : official journal of the Japanese Society of Hypertension.
2012 Jan; 35(1):48-54. doi:
10.1038/hr.2011.140. [PMID: 21900942] - Arun Prasath Lakshmanan, Rajarajan A Thandavarayan, Suresh S Palaniyandi, Flori R Sari, Harima Meilei, Vijayasree V Giridharan, Vivian Soetikno, Kenji Suzuki, Makoto Kodama, Kenichi Watanabe. Modulation of AT-1R/CHOP-JNK-Caspase12 pathway by olmesartan treatment attenuates ER stress-induced renal apoptosis in streptozotocin-induced diabetic mice.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2011 Dec; 44(5):627-34. doi:
10.1016/j.ejps.2011.10.009. [PMID: 22033153] - Dimitrios Ntountaniotis, Gregor Mali, Simona Golic Grdadolnik, Maria Halabalaki, Halabalaki Maria, Alexios-Leandros Skaltsounis, Constantinos Potamitis, Eleni Siapi, Petros Chatzigeorgiou, Michael Rappolt, Thomas Mavromoustakos. Thermal, dynamic and structural properties of drug AT1 antagonist olmesartan in lipid bilayers.
Biochimica et biophysica acta.
2011 Dec; 1808(12):2995-3006. doi:
10.1016/j.bbamem.2011.08.001. [PMID: 21843501] - Debra Conte, Jose Viscarra, Akira Nishiyama, Rudy M Ortiz. Chronic angiotensin receptor blockade suppresses intracardiac angiotensin II in angiotensin II-infused rats.
Experimental biology and medicine (Maywood, N.J.).
2011 Dec; 236(12):1449-53. doi:
10.1258/ebm.2011.011159. [PMID: 22087022] - E Imai, J C N Chan, S Ito, T Yamasaki, F Kobayashi, M Haneda, H Makino. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.
Diabetologia.
2011 Dec; 54(12):2978-86. doi:
10.1007/s00125-011-2325-z. [PMID: 21993710] - Lorenzo A Cal, Lucia Dal Maso, Paola Caielli, Elisa Pagnin, Maria Fusaro, Paul A Davis, Achille C Pessina. Effect of olmesartan on oxidative stress in hypertensive patients: mechanistic support to clinical trials derived evidence.
Blood pressure.
2011 Dec; 20(6):376-82. doi:
10.3109/08037051.2011.575570. [PMID: 21504378] - Y Koc, E Mazi, T Sakaci, T Basturk, A Batuhan Damar, E Ahbap, A Unsal, F Borlu. Effect of Olmesartan on serum cystatin C levels in the patients with essential hypertension.
European review for medical and pharmacological sciences.
2011 Dec; 15(12):1389-94. doi:
. [PMID: 22288300] - Michiya Igase, Hiroshi Yokoyama, Carlos M Ferrario. Attenuation of hypertension-mediated glomerulosclerosis in conjunction with increased angiotensin (1-7).
Therapeutic advances in cardiovascular disease.
2011 Dec; 5(6):297-304. doi:
10.1177/1753944711429343. [PMID: 22089474] - Enyu Imai. [Series: Clinical study from Japan and its reflections; Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT)].
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.
2011 Nov; 100(11):3386-92. doi:
10.2169/naika.100.3386. [PMID: 22250438] - Keiji Kusumoto, Hideki Igata, Mami Ojima, Ayako Tsuboi, Mitsuaki Imanishi, Fuminari Yamaguchi, Hiroki Sakamoto, Takanobu Kuroita, Naohiro Kawaguchi, Nobuhiro Nishigaki, Hideaki Nagaya. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
European journal of pharmacology.
2011 Nov; 669(1-3):84-93. doi:
10.1016/j.ejphar.2011.07.014. [PMID: 21816148] - Yasuhiko Kanaguchi, Yusuke Suzuki, Ken Osaki, Takeshi Sugaya, Satoshi Horikoshi, Yasuhiko Tomino. Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2011 Nov; 26(11):3465-73. doi:
10.1093/ndt/gfr110. [PMID: 21525165] - Hisashi Hidaka, Takahide Nakazawa, Akitaka Shibuya, Tsutomu Minamino, Juichi Takada, Yoshiaki Tanaka, Yusuke Okuwaki, Masaaki Watanabe, Wasaburo Koizumi. Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: a randomized controlled trial.
Journal of gastroenterology.
2011 Nov; 46(11):1316-23. doi:
10.1007/s00535-011-0449-z. [PMID: 21850387] - Michio Fukuda, Tamaki Wakamatsu-Yamanaka, Masashi Mizuno, Toshiyuki Miura, Tatsuya Tomonari, Yoko Kato, Tadashi Ichikawa, Sota Miyagi, Yuichi Shirasawa, Akinori Ito, Atsuhiro Yoshida, Genjiro Kimura. Angiotensin receptor blockers shift the circadian rhythm of blood pressure by suppressing tubular sodium reabsorption.
American journal of physiology. Renal physiology.
2011 Nov; 301(5):F953-7. doi:
10.1152/ajprenal.00167.2011. [PMID: 21865265] - Sum Lam. Azilsartan: a newly approved angiotensin II receptor blocker.
Cardiology in review.
2011 Nov; 19(6):300-4. doi:
10.1097/crd.0b013e31822e9ba3. [PMID: 21983318]
